(BEAM) Beam Therapeutics - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US07373V1052
Stock:
Total Rating 32
Risk 67
Buy Signal -0.62
| Risk 5d forecast | |
|---|---|
| Volatility | 86.0% |
| Relative Tail Risk | -15.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.40 |
| Alpha | -28.24 |
| Character TTM | |
|---|---|
| Beta | 2.072 |
| Beta Downside | 3.158 |
| Drawdowns 3y | |
|---|---|
| Max DD | 67.74% |
| CAGR/Max DD | -0.15 |
EPS (Earnings per Share)
Revenue
Risks
Technicals:
choppy
Description: BEAM Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, and BEAM-104, a cell therapy for development in sickle cell disease and beta-thalassemia; and BEAM-201 and other potential ex vivo CAR-T therapies. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -414.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.27 > 0.02 and ΔFCF/TA -14.46 > 1.0 |
| NWC/Revenue: 1644 % < 20% (prev 222.9%; Δ 1422 % < -1%) |
| CFO/TA -0.26 > 3% & CFO -338.2m > Net Income -414.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 6.02 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.6m) vs 12m ago 24.46% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 4.49% > 50% (prev 29.85%; Δ -25.36% > 0%) |
| Interest Coverage Ratio: -19.47 > 6 (EBITDA TTM -430.1m / Interest Expense TTM 23.2m) |
Altman Z'' -8.32
| A: 0.70 (Total Current Assets 1.10b - Total Current Liabilities 182.6m) / Total Assets 1.31b |
| B: -1.44 (Retained Earnings -1.89b / Total Assets 1.31b) |
| C: -0.36 (EBIT TTM -452.2m / Avg Total Assets 1.24b) |
| D: -5.47 (Book Value of Equity -1.89b / Total Liabilities 345.1m) |
| Altman-Z'' Score: -8.32 = D |
Beneish M
| DSRI: none (Receivables none/none, Revenue 55.7m/349.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.85 (AQ_t 0.01 / AQ_t-1 0.01) |
| SGI: 0.16 (Revenue 55.7m / 349.6m) |
| TATA: -0.06 (NI -414.6m - CFO -338.2m) / TA 1.31b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of BEAM shares?
As of February 28, 2026, the stock is trading at USD 28.46 with a total of 1,617,743 shares traded.
Over the past week, the price has changed by +3.15%, over one month by -7.30%, over three months by +12.36% and over the past year by +4.98%.
Over the past week, the price has changed by +3.15%, over one month by -7.30%, over three months by +12.36% and over the past year by +4.98%.
Is BEAM a buy, sell or hold?
Beam Therapeutics has received a consensus analysts rating of 4.41.
Therefore, it is recommended to buy BEAM.
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BEAM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 49.5 | 74% |
| Analysts Target Price | 49.5 | 74% |
BEAM Fundamental Data Overview February 26, 2026
P/S = 58.8253
P/B = 2.473
Revenue TTM = 55.7m USD
EBIT TTM = -452.2m USD
EBITDA TTM = -430.1m USD
Long Term Debt = 151.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 151.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.35b USD (3.28b + Debt 151.4m - CCE 1.07b)
Interest Coverage Ratio = -19.47 (Ebit TTM -452.2m / Interest Expense TTM 23.2m)
EV/FCF = -6.68x (Enterprise Value 2.35b / FCF TTM -352.4m)
FCF Yield = -14.97% (FCF TTM -352.4m / Enterprise Value 2.35b)
FCF Margin = -632.6% (FCF TTM -352.4m / Revenue TTM 55.7m)
Net Margin = -744.4% (Net Income TTM -414.6m / Revenue TTM 55.7m)
Gross Margin = unknown ((Revenue TTM 55.7m - Cost of Revenue TTM 411.8m) / Revenue TTM)
Tobins Q-Ratio = 1.79 (Enterprise Value 2.35b / Total Assets 1.31b)
Interest Expense / Debt = 7.20% (Interest Expense 10.9m / Debt 151.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -357.2m (EBIT -452.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.02 (Total Current Assets 1.10b / Total Current Liabilities 182.6m)
Debt / Equity = 0.16 (Debt 151.4m / totalStockholderEquity, last quarter 966.0m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -116.5m / EBITDA -430.1m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -116.5m / FCF TTM -352.4m)
Total Stockholder Equity = 967.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.41% (Net Income -414.6m / Total Assets 1.31b)
RoE = -42.86% (Net Income TTM -414.6m / Total Stockholder Equity 967.4m)
RoCE = -40.42% (EBIT -452.2m / Capital Employed (Equity 967.4m + L.T.Debt 151.4m))
RoIC = -36.93% (negative operating profit) (NOPAT -357.2m / Invested Capital 967.4m)
WACC = 13.20% (E(3.28b)/V(3.43b) * Re(13.55%) + D(151.4m)/V(3.43b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 13.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.37%
[DCF] Fair Price = unknown (Cash Flow -352.4m)
EPS Correlation: 28.54 | EPS CAGR: 61.47% | SUE: 3.49 | # QB: 1
Revenue Correlation: -32.24 | Revenue CAGR: -35.79% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.17 | Chg7d=-0.012 | Chg30d=-0.012 | Revisions Net=+1 | Analysts=8
EPS current Year (2026-12-31): EPS=-4.63 | Chg7d=-0.047 | Chg30d=-0.039 | Revisions Net=-2 | Growth EPS=-472.2% | Growth Revenue=-68.2%
EPS next Year (2027-12-31): EPS=-4.53 | Chg7d=+0.016 | Chg30d=+0.016 | Revisions Net=-1 | Growth EPS=+2.2% | Growth Revenue=+45.6%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
P/B = 2.473
Revenue TTM = 55.7m USD
EBIT TTM = -452.2m USD
EBITDA TTM = -430.1m USD
Long Term Debt = 151.4m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.7m USD (from shortTermDebt, last quarter)
Debt = 151.4m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -116.5m USD (from netDebt column, last quarter)
Enterprise Value = 2.35b USD (3.28b + Debt 151.4m - CCE 1.07b)
Interest Coverage Ratio = -19.47 (Ebit TTM -452.2m / Interest Expense TTM 23.2m)
EV/FCF = -6.68x (Enterprise Value 2.35b / FCF TTM -352.4m)
FCF Yield = -14.97% (FCF TTM -352.4m / Enterprise Value 2.35b)
FCF Margin = -632.6% (FCF TTM -352.4m / Revenue TTM 55.7m)
Net Margin = -744.4% (Net Income TTM -414.6m / Revenue TTM 55.7m)
Gross Margin = unknown ((Revenue TTM 55.7m - Cost of Revenue TTM 411.8m) / Revenue TTM)
Tobins Q-Ratio = 1.79 (Enterprise Value 2.35b / Total Assets 1.31b)
Interest Expense / Debt = 7.20% (Interest Expense 10.9m / Debt 151.4m)
Taxrate = 21.0% (US default 21%)
NOPAT = -357.2m (EBIT -452.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.02 (Total Current Assets 1.10b / Total Current Liabilities 182.6m)
Debt / Equity = 0.16 (Debt 151.4m / totalStockholderEquity, last quarter 966.0m)
Debt / EBITDA = 0.27 (negative EBITDA) (Net Debt -116.5m / EBITDA -430.1m)
Debt / FCF = 0.33 (negative FCF - burning cash) (Net Debt -116.5m / FCF TTM -352.4m)
Total Stockholder Equity = 967.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.41% (Net Income -414.6m / Total Assets 1.31b)
RoE = -42.86% (Net Income TTM -414.6m / Total Stockholder Equity 967.4m)
RoCE = -40.42% (EBIT -452.2m / Capital Employed (Equity 967.4m + L.T.Debt 151.4m))
RoIC = -36.93% (negative operating profit) (NOPAT -357.2m / Invested Capital 967.4m)
WACC = 13.20% (E(3.28b)/V(3.43b) * Re(13.55%) + D(151.4m)/V(3.43b) * Rd(7.20%) * (1-Tc(0.21)))
Discount Rate = 13.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.37%
[DCF] Fair Price = unknown (Cash Flow -352.4m)
EPS Correlation: 28.54 | EPS CAGR: 61.47% | SUE: 3.49 | # QB: 1
Revenue Correlation: -32.24 | Revenue CAGR: -35.79% | SUE: -0.03 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-1.17 | Chg7d=-0.012 | Chg30d=-0.012 | Revisions Net=+1 | Analysts=8
EPS current Year (2026-12-31): EPS=-4.63 | Chg7d=-0.047 | Chg30d=-0.039 | Revisions Net=-2 | Growth EPS=-472.2% | Growth Revenue=-68.2%
EPS next Year (2027-12-31): EPS=-4.53 | Chg7d=+0.016 | Chg30d=+0.016 | Revisions Net=-1 | Growth EPS=+2.2% | Growth Revenue=+45.6%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)